Patient stratification based on pTNM stage showed that OS improvement in response to sequential paclitaxel treatment in patients with low VSNL1 and/or CD44v expression was the greatest in patients with stage IIIB/IIIC GC (Fig. 3). This evidence concerns the gene VSNL1 and gastric cancer.